Transine Therapeutics Appoints Industry Veteran Jan Thirkettle Ph.D. as CEO
Mon, Jul 5, 2021
Transine Therapeutics today announced the appointment of Jan Thirkettle, Ph.D. as its Chief Executive Officer.
Transine Therapeutics Closes Extended Seed Funding of £9.1 million
Tue, Jun 1, 2021
Transine Therapeutics announces that it successfully secured £9.1 million in seed funding.
Transine founders identify key mechanisms of SINEUP® action
Fri, Jan 1, 2021
Transine co-founder, Professor Piero Carninci’s lab recently contributed new seminal understandings to the SINEUP® field.
Head of Licensing recognised as one of 2020 Movers and Shakers in BioBusiness
Tue, Nov 10, 2020
The Movers and Shakers in BioBusiness report was released in advance of the BioBeat20 Summit: Accelerating Data-driven Health, on Tuesday 17th November 2020, in partnership with the Francis Crick Institute.
BIO-Europe: VP of R&D and Operations discusses the future of neurodegeneration treatment
Thu, Oct 22, 2020
Dr. Sarah Cole, our VP of R&D and Operations, was invited to participate in an expert panel as part of the BIO-Europe conference.